Table 6.

Odds ratios (95 % CI) for ER-defined breast cancer across plasma enterolactone concentration (low/high) in women from the MDC cohort, 1991 to 2004

ENL concentration
P for heterogeneity
LowHigh
ENL concentration (nmol/L), median (range)8.4 (0.3-16.1)26.3 (16.1-334.4)
    Cases/controls204/366162/367
    OR (95% CI)1.000.75 (0.58-0.98)
    ERα (−) tumors
        Cases/controls27/36625/367
        OR (95% CI)1.000.86 (0.48-1.54)
    ERα (+) tumors
        Cases/controls175/366134/367
        OR (95% CI)1.000.73 (0.55-0.97)0.62*
    ERβ (−) tumors
        Cases/controls113/36672/367
        OR (95% CI)1.000.60 (0.43-0.85)
    ERβ (+) tumors
        Cases/controls91/36690/367
        OR (95% CI)1.000.94 (0.67-1.33)0.04
    ERα (+)/ERβ (−) tumors
        Cases/controls93/36659/367
        OR (95% CI)1.000.59 (0.41-0.86)
    ERα (+)/ERβ (+) tumors
        Cases/controls82/36675/367
        OR (95 % CI)1.000.90 (0.63-1.28)0.08
  • NOTE: Adjusted for age, date of blood collection, weight, height, smoking status, educational status, and current use of menopausal hormone therapy.

  • * Test of heterogeneity between ERα (−) and ERα (+) tumors.

  • Test of heterogeneity between ERβ (−) and ERβ (+) tumors.

  • Test of heterogeneity between ERα (+)/ERβ (−) and ERα (+)/ERβ (+) tumors.